Hepcidin contributes to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss

Abstract

Patients with Alzheimer’s disease (AD) often have lower bone mass than healthy individuals. However, the mechanisms underlying this change remain elusive. Previously, we found that Tg2576 mice, an AD animal model that ubiquitously expresses Swedish mutant amyloid precursor protein (APP_swe), shows osteoporotic changes, reduced bone formation, and increased bone resorption. To understand how bone deficits develop in Tg2576 mice, we used a multiplex antibody array to screen for serum proteins that are altered in Tg2576 mice and identified hepcidin, a master regulator of iron homeostasis. We further investigated hepcidin’s function in bone homeostasis and found that hepcidin levels were increased not only in the serum but also in the liver, muscle, and osteoblast (OB) lineage cells in Tg2576 mice at both the mRNA and protein levels. We then generated mice selectively expressing hepcidin in hepatocytes or OB lineage cells, which showed trabecular bone loss and increased osteoclast (OC)-mediated bone resorption. Further cell studies suggested that hepcidin increased OC precursor proliferation and differentiation by downregulating ferroportin (FPN) expression and increasing intracellular iron levels. In OB lineage cells, APP_swe enhanced hepcidin expression by inducing ER stress and increasing OC formation, in part through hepcidin. Together, these results suggest that increased hepcidin expression in hepatocytes and OB lineage cells in Tg2576 mice contributes to enhanced osteoclastogenesis and trabecular bone loss, identifying the hepcidin-FPN-iron axis as a potential therapeutic target to prevent AD-associated bone loss.

References

[1] Melton LJ 3rd, Beard CM, Kokmen E, Atkinson EJ, O’Fallon WM. Fracture risk in patients with Alzheimer’s disease. J. Am. Geriatr. Soc., 1994, 42: 614-619

[2] Tysiewicz-Dudek M, Pietraszkiewicz F, Drozdzowska B. Alzheimer’s disease and osteoporosis: common risk factors or one condition predisposing to the other? Ortop. Traumatol. Rehabil., 2008, 10: 315-323

[3] Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther. Adv. Musculoskelet. Dis., 2012, 4: 61-76

[4] Lufkin EG et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med., 1992, 117: 1-9

[5] Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Min. Res, 1996, 11: 1043-1051

[6] Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys. Res Commun., 2001, 288: 275-279

[7] Tsay J et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood, 2010, 116: 2582-2589

[8] Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev., 2010, 31: 266-300

[9] Pan JX et al. APP promotes osteoblast survival and bone formation by regulating mitochondrial function and preventing oxidative stress. Cell Death Dis., 2018, 9

[10] Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov., 2012, 11: 234-250

[11] Akiyama H et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging, 2000, 21: 383-421

[12] McLean RR. Proinflammatory cytokines and osteoporosis. Curr. Osteoporos. Rep., 2009, 7: 134-139

[13] Moon SJ et al. Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int. J. Mol. Med., 2013, 31: 769-777

[14] Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann. Transl. Med., 2015, 3: 136

[15] Cui S et al. APPswe/Abeta regulation of osteoclast activation and RAGE expression in an age-dependent manner. J. Bone Min. Res., 2011, 26: 1084-1098

[16] Xia WF et al. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J. Bone Min. Res., 2013, 28: 2122-2135

[17] Zhang M et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem., 2002, 277: 44005-44012

[18] Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem., 2001, 276: 7806-7810

[19] Pigeon C et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem., 2001, 276: 7811-7819

[20] Nemeth E et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306: 2090-2093

[21] Pospisilova D, Mims MP, Nemeth E, Ganz T, Prchal JT. DMT1 mutation: response of anemia to darbepoetin administration and implications for iron homeostasis. Blood, 2006, 108: 404-405

[22] Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science, 2012, 338: 768-772

[23] Nemeth E et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest., 2004, 113: 1271-1276

[24] Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc. Natl Acad. Sci. USA, 2004, 101: 9263-9265

[25] Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood, 2006, 108: 3204-3209

[26] Kanamori Y et al. Hepcidin and IL-1beta. Vitam. Horm., 2019, 110: 143-156

[27] Armitage AE et al. Hepcidin regulation by innate immune and infectious stimuli. Blood, 2011, 118: 4129-4139

[28] Smith CL et al. IL-22 regulates iron availability in vivo through the induction of hepcidin. J. Immunol., 2013, 191: 1845-1855

[29] Ramos E et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology, 2011, 53: 1333-1341

[30] Andriopoulos B Jr et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet., 2009, 41: 482-487

[31] Meynard D et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat. Genet., 2009, 41: 478-481

[32] Vecchi C et al. ER stress controls iron metabolism through induction of hepcidin. Science, 2009, 325: 877-880

[33] Canali S et al. The SMAD pathway is required for hepcidin response during endoplasmic reticulum stress. Endocrinology, 2016, 157: 3935-3945

[34] Zhao GY, Di DH, Wang B, Huang X, Xu YJ. Effects of mouse hepcidin 1 treatment on osteoclast differentiation and intracellular iron concentration. Inflammation, 2015, 38: 718-727

[35] Xu Z et al. The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss. Bone, 2017, 94: 152-161

[36] Wang L et al. Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo. J. Biol. Chem., 2018, 293: 9248-9264

[37] Hsiao K et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274: 99-102

[38] Balogh E, Paragh G, Jeney V. Influence of iron on bone homeostasis. Pharmaceuticals (Basel), 2018, 11: 107

[39] Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharm. Sci., 2009, 30: 346-355

[40] Parfitt AM et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Invest., 1983, 72: 1396-1409

[41] Hamrick MW et al. Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin. Bone, 2006, 39: 845-853

[42] Postic C et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem., 1999, 274: 305-315

[43] Xiong L et al. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc. Natl Acad. Sci. USA, 2015, 112: 3487-3492

[44] Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165-176

[45] Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA, 1998, 95: 3597-3602

[46] Teitelbaum SL. Bone resorption by osteoclasts. Science, 2000, 289: 1504-1508

[47] Altamura S et al. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload. Cell Metab., 2014, 20: 359-367

[48] Fernandes A et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood, 2009, 114: 437-443

[49] Ledesma-Colunga MG et al. Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. Bone, 2020, 137: 115400

[50] Sham RL et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood cells, molecules Dis., 2005, 34: 157-161

[51] Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer’s disease: a novel neuronal trigger for inflammation and Alzheimer’s pathology. J. Neuroinflammation, 2009, 6

[52] Uddin MS et al. Molecular mechanisms of ER stress and UPR in the pathogenesis of Alzheimer’s disease. Mol. Neurobiol., 2020, 57: 2902-2919

[53] Koyama M et al. Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol., 2014, 306: H1314-H1323

[54] Guo JP et al. Iron chelation inhibits osteoclastic differentiation in vitro and in Tg2576 mouse model of Alzheimer’s dsease. PLoS ONE, 2015, 10: e0139395

[55] Elefteriou F, Yang X. Genetic mouse models for bone studies–strengths and limitations. Bone, 2011, 49: 1242-1254

[56] Yan N, Zhang JIron. metabolism, ferroptosis, and the links with Alzheimer’s dsease. Front Neurosci., 2019, 13: 1443

[57] Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C. Iron and Alzheimer’s disease: from pathogenesis to therapeutic implications. Front Neurosci., 2018, 12: 632

[58] Sternberg Z et al. Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer’s disease. Aging Dis., 2017, 8: 215-227

[59] Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature, 2008, 454: 455-462

[60] Hashimoto S, Saido TC. Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer’s disease. Open Biol, 2018, 8: 180024

[61] Oliveira SJ et al. ER stress-inducible factor CHOP affects the expression of hepcidin by modulating C/EBPalpha activity. PLoS ONE, 2009, 4: e6618

[62] Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 2003, 102: 783-788

[63] Sasu BJ et al. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol. Dis, 2010, 45: 238-245

[64] Senates E et al. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metab. Syndr. Relat. Disord., 2011, 9: 287-290

[65] Oustamanolakis P et al. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 2011, 23: 262-268

[66] Manolagas SC. Role of cytokines in bone resorption. Bone, 1995, 17: 63S-67S

[67] Chang Y et al. Synovial fluid interleukin-16 contributes to osteoclast activation and bone loss through the JNK/NFATc1 signaling cascade in patients with periprosthetic joint infection. Int. J. Mol. Sci, 2020, 21: 2904

[68] Yamada A et al. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology, 2007, 120: 573-579

[69] Shen GS et al. Hepcidin1 knockout mice display defects in bone microarchitecture and changes of bone formation markers. Calcif. Tissue Int., 2014, 94: 632-639

[70] Wang X et al. Iron-induced oxidative stress stimulates osteoclast differentiation via NF-kappaB signaling pathway in mouse model. Metabolism, 2018, 83: 167-176

[71] Hayman AR, Cox TM. Purple acid phosphatase of the human macrophage and osteoclast. Characterization, molecular properties, and crystallization of the recombinant di-iron-oxo protein secreted by baculovirus-infected insect cells. J. Biol. Chem., 1994, 269: 1294-1300

Funding

U.S. Department of Veterans Affairs (Department of Veterans Affairs)(BX000838)